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Background: Home mechanical ventilation is usually initiated in hospital. However, cost-
effectiveness of inpatient set up has never been compared to outpatient adaptation in a ran-
domized design. A Prospective, multicenter, non-inferiority trial was conducted comparing the
effectiveness of adaptation to noninvasive mechanical ventilation (NIMV) performed in the
ambulatory or hospital setting in patients with chronic respiratory failure secondary to restric-
tive thoracic disease, obesity-hypoventilation syndrome or neuromuscular disease.
Methods: The study included 53 candidates for NIMV, randomized to ambulatory adaptation
(AA) (n Z 27) or hospital adaptation (HA) (n Z 26). The patients’ characteristics were re-
corded before establishing ventilation and at 1 and 6 months after. The main outcome variable
was PaCO2 decrease at 6 months following initiation of NIMV. The direct costs of the two inter-
ventions were compared.
Results: Before starting NIMV, PaCO2 was 50.4  6.8 mmHg in the AA group and
50.3  5.7 mmHg in the HA group. At 6 months of NIMV use, a significant improvement in PaCO2
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Ambulatory adaptation to noninvasive ventilation 1015relative to baseline was found in both groups: mean (95% CI) PaCO2 decrease was 4.9 (2.3; 7.4)
mmHg in AA and 3.3 (1.4; 5.1) mmHg in HA. The direct calculated cost was 1500 euros per pa-
tient in AA and 2692 euros per patient in HA.
Conclusions: Adaptation to NIMV in the ambulatory setting is not inferior to hospital adaptation
in terms of therapeutic equivalence in stable patients with chronic respiratory failure second-
ary to restrictive thoracic disease, obesity-hypoventilation syndrome or neuromuscular dis-
ease. Outpatient adaptation may represent a cost saving for the healthcare system.
Clinical Trial: Identifier number NCT00698958 at www.clinicaltrials.gov.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Restrictive thoracic disease, obesity-hypoventilation syn-
drome and neuromuscular disease are important causes of
chronic hypercapnic respiratory failure [1]. Although there
are no long-term randomized controlled studies investigating
noninvasive home mechanical ventilation (NIMV in patients
with theseconditions, it is considered thetreatmentofchoice
in cases of established hypercapnic respiratory failure [2].
NIMV improves the patient’s blood gas status, health-related
quality of life (HRQL), and physical activity, and results in
increased survival as compared to historical cohorts [3e8].
The process by which a patient initiates and adapts to
NIMV is complex and involves a series of decisions that can
determine the success of this therapy. Some of the most
important choices are the type and the characteristics of the
ventilator, and the setting where adaptation will be carried
out. Regarding this latter factor, it is well recognized that
patientswith acutedisease should undergo adaptation during
hospital admission [9], but other options have been proposed
for patients initiating ventilation in a stable phase of disease.
Patients are often hospitalized when NIMV is started [10]
to enable better monitoring of the adaptation process.
However, hospitalization is expensive, there may be wait-
ing lists, and it has not been conclusively demonstrated
that this policy leads to better compliance with the pre-
scription [11,12]. Thus, some authors prefer to carry out
NIMV adaptation in the sleep laboratory [13,14], whereas
others advocate ambulatory adaptation in an outpatient
clinic or the patient’s home [11,12,15].
Because few studies have evaluated the superiority of
one setting over another for adapting to NIMV, the choice
has been based on the preferences or possibilities of each
team of health professionals. The aim of the present study
is to evaluate whether the effectiveness of adaptation to
NIMV on an ambulatory basis is comparable to hospital
adaptation in patients with chronic respiratory failure
secondary restrictive thoracic disease, obesity-
hypoventilation syndrome or neuromuscular disease and
to analyze the associated cost of these two approaches.
Patients and methods
Study design
This is a prospective clinical trial (identifier NCT00698958
at www.clinicaltrials.gov) with randomized assignment ofpatients to two parallel groups. The study evaluated non-
inferiority in terms of effectiveness and associated cost of
ambulatory or hospital-based NIMV adaptation in patients
with chronic respiratory failure secondary to restrictive
thoracic disease, obesity-hypoventilation syndrome or
neuromuscular disease in two teaching hospitals in Barce-
lona (Spain). The study protocol (03-0222) was approved by
the Ethics Committees for Clinical Research of the partici-
pating centers and by the Spanish Agency for Medicines and
Healthcare Products.Patients
In the period of 2004e2008, all patients 18e80 years of age
with chronic respiratory failure secondary to restrictive
thoracic disease, obesity-hypoventilation syndrome or
slowly progressive neuromuscular disease and having an
indication for NIMV were informed of the study. All those
who gave consent to participate were included and
randomly assigned to one of two parallel groups: ambula-
tory adaptation (AA) or hospital adaptation (HA).
The indication for NIMV was based on consensus con-
ference criteria [16] and Spanish guidelines [17]. Briefly,
the criteria included clinical symptoms (dyspnea, fatigue,
orthopnea, and morning headache) and one of the
following: 1) chronic hypercapnia (PaCO2 > 45 mmHg) in a
stable patient, or 2) nocturnal oxygen saturation <90%
(CT90) during at least 30% of the night. Patients in whom
NIMV was contraindicated [17], those with acute disease,
and those requiring invasive airway access through a tra-
cheostomy were excluded. Patients who were residing
more than 50 km from the participating hospitals were also
excluded.
Sample size calculation: with 26 evaluable patients per
group, the study had an 80% power to test the non-
inferiority of ambulatory adaptation against hospital
adaptation for the main effectiveness variable, post-
adaptation PaCO2 decrease at 6 months.Outcome variables
The main outcome variable was reduction in PaCO2 at 6
months following the start of NIMV with respect to PaCO2
baseline value before starting NIMV. The secondary vari-
ables considered were pharmacoeconomic assessment and
health-related quality of life.
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Initial assessment
Before starting NIMV, all patients underwent pulmonary
function testing [18e20], blood gas determination [21]
nocturnal pulse oximetry with the patient breathing room
air (Pulsox-3i, Minolta), and the 6-min walk test (6MWT)
[22]. Health-related quality of life (HRQL) was evaluated
using the Spanish version of the SF-36 [23,24], a generic
instrument that includes 26 questions distributed in 8 areas
or domains: physical function, role limitations due to
physical problems, vitality, bodily pain, general health
perception, social functioning, role limitations due to
emotional problems, and general mental health. The total
score on the SF-36 ranges from 0 to 100, with higher scores
indicating better HRQL.
Initiation of noninvasive ventilation
Patients undergoing HA were admitted to a respiratory
ward and patients undergoing AA were referred to a Day
Hospital facility. The method of initiation was the same in
both groups [17] and was conducted by assistant pneu-
mologists and respiratory nurses with broad experience in
ventilation. Daily ventilation sessions of at least 2 or
3 h were performed in order to increase tolerance of NIMV
and to train patients or their carers in the basic handling of
the ventilator. Initially, adaptation to a volume-cycled
ventilator (Breas PV501, Breas Medical, Compiegne,
France) was attempted. In patients unable to adapt to this
option, a pressure-cycled system (BiPAP, Respironics, Inc,
Monroeville, PA) was tried. The ventilator parameters were
set, and the efficacy of the ventilation was evaluated tak-
ing into account the patient’s tolerance, oxygen saturation,
arterial blood gases while awake at 1 h after starting
ventilation, and nocturnal pulse oximetry. The primary goal
of NIMV adaptation in these patients was to normalize
daytime PaCO2 while awake and using the ventilator. In the
AA group, pulse oximetry was carried out at home. All pa-
tients were counseled in its progressive use, at least during
the entire night, regardless of the assigned group.
Treatment was considered effective when, after 1
month, PaCO2 value with the patient breathing room air
normalized or decreased by at least 5 mmHg and the pa-
tient was able to use mechanical ventilation at least 4 h per
night. The possibility of hospital adaptation was considered
in cases of adaptation failure in patients assigned to AA.
Follow-up
All patients were given an emergency telephone number to
contact for medical problems and another number for
mechanical problems with the ventilator (property of the
Catalan Health System).
Once patients had adapted to NIMV, they were visited at
home 15 days later by a respiratory nurse, and were seen at
1, 3 and 6 months in the hospital by assistant pneumolo-
gists; unscheduled visits could also be solicited. A clinical
interview was performed at all visits to record NIMV-related
adverse effects, the number of hospitalizations required,
objective daily compliance assessed through the counter
installed on the system, and the clinical benefits obtained.
In addition, forced spirometry and room-air arterial bloodgases testing were performed at the 1- and 6-month visits,
and the lung volume, inspiratory and expiratory pressures,
6MWT, and HRQL were again evaluated at the 6-month
visit.
Pharmacoeconomic assessment
The perspective of the pharmacoeconomic assessment was
that of the National Health Service; thus, indirect costs
were not considered. Cost information was collected from
each of the adaptation groups: number of hospitalization
days in the hospital-based approach and use of health re-
sources (outpatient medical visits and visits to the patient’s
home by health workers). In addition, data were compiled
on the use of health resources over the 6 months following
adaptation (admissions for respiratory complications,
emergency room visits, unscheduled outpatient visits, and
additional testing). The direct cost of NIMV adaptation,
including the 6-month cost of health resource use, was
calculated for each adaptation approach, using third party
billing data from 2008, provided by the hospital financial
management. The cost of the ventilator systems used was
not included in the model.
Statistical analysis
Descriptive data are expressed as frequencies and per-
centages for qualitative and ordinal variables, and as the
mean and standard deviation (SD) for quantitative
variables.
An ANCOVA model including the baseline PaCO2 value as
covariate was used to assess non-inferiority. Least square
means and 95% CI are estimated from that model. Once
non-inferiority was proven, a cost-minimization approach
was applied, assuming equivalence of the two approaches
in terms of PaCO2 improvement. A decision tree analysis
model was built, based on the efficacy results of the two
strategies and their clinical and economic consequences.
The rest of continuous variables were compared either
using an ANCOVA model to test the baseline-adjusted
changes from baseline for between-group comparisons
and standard ANOVA for within-group comparisons, or t-test
for non-randomized baseline comparisons. The Fisher
exact-test was used for categorical variables.
Results
Seventy patients met the selection criteria for the study
and each patient was randomized to one of the two adap-
tation groups. Ultimately, ventilation treatment was not
initiated in 17 patients, which left a final population of 53
study patients (Fig. 1). The characteristics of the 70 pa-
tients randomized for the study (treated and untreated) are
shown in Table 1.
Among the 53 treated patients, 27 underwent AA and 26
HA. The mean (standard deviation [SD]) time interval be-
tween randomization and the start of adaptation was 68.94
(67.10) days for the hospital group and 26.76 (27.18) days
for the ambulatory group (pZ 0.0054). The characteristics
of the patients in each adaptation group before starting
Figure 1 Flow chart of the study population.
Ambulatory adaptation to noninvasive ventilation 1017mechanical ventilation are shown in Table 2. The ventila-
tion mode, ventilator parameters, and the patients’ blood
gas and nocturnal pulse oximetry results following
adequate adaptation are summarized in Table 3. Volume-
cycled ventilation had to be changed to pressure ventila-
tion in 3 patients (2 AA, 1 HA). The mean (SD) length of stay
for hospital adaptation was 6.25 (2.18) days, and the mean
duration of outpatient attention for ambulatory adaptation
was 2.71 (0.99) sessions. None of the AA patients ultimately
required hospital admission for adaptation to the
ventilator.
All patients in both groups completed the study. A
decrease in PaCO2 relative to baseline values was docu-
mented at 1 month and 6 months of NIMV initiation in both
groups. At 1 month, mean (SD) PaCO2 was 47.56 (5.29)
mmHg in the AA group, with a 2.9 mmHg reduction (95% CI
1.0e4.8), and 47.46 (5.49) mmHg in the HA group, with a
2.8 mmHg reduction (95% CI 0.9e4.6). The PaCO2 decreaseat 1 month was not significantly different between the two
adaptation groups (p Z 0.9176). At 6 months following the
start of NIMV, there was a reduction in PaCO2 with respect
to baseline in both groups: 4.9 (95% CI 2.3e7.4) mmHg in AA
patients and 3.3 (95% CI 1.4e5.1) mmHg in HA patients. The
difference between the two groups was 1.6 (95% CI 4.6 to
1.5) mmHg in favor of ambulatory adaptation. Significant
changes in both groups (AA, HA) with respect to baseline
were found for PaO2 and PaCO2, but not for the other var-
iables studied (Table 4).
In 34 patients (17 AA and 17 HA, patients from one of the
two centers) we were able to analyze quality of life, at
baseline and at 6 months of NIMV initiation, which showed
no deterioration in any domain and a significant improve-
ment in the physical function dimension in both adaptation
groups (Table 5). There were no significant differences in
the magnitude of change from baseline in any dimension
according to adaptation group.
Table 1 Baseline characteristics of the group of ran-
domized patients, divided according to whether they ulti-
mately underwent treatment or not.
Untreated
(n Z 17)
Treated
(n Z 53)
p
Age, years 62.6  16.7 65.0  13.0 0.539
Sex
Males 10 (58.8%) 19 (35.9%) 0.156
Smoker
Current 0 (0%) 3 (5.8%) 0.586
Past 6 (35.3%) 16 (31.4%)
Never 11 (64.7%) 34 (62.8%)
Disease
Restrictive thoracic
disease
13 (76.6%) 29 (54.7%) 0.280a
Kyphoscoliosis 5 (38.5%) 16 (55.2%)
Tuberculosis
sequelae
5 (38.5%) 11 (37.9%)
Pleural thickening 3 (23%) 2 (6.9%)
OHS 2 (11.7%) 9 (17.0%)
Neuromuscular 2 (11.7%) 15 (28.3%)
Pulmonary function test
FVC, % predicted 39.8 (8.6) 44.1 (15.7) 0.157
FEV1, % predicted 37.1 (12.6) 43.8 (16.5) 0.132
FEV1/FVC, % 71.9 (19.3) 62.1 (22.4) 0.113
TLC, % predicted 60.1 (19.2) 66.4 (21.2) 0.276
RV, % predicted 107.4 (74.7) 85.2 (35.6) 0.252
RV/TLC, % 70.6 (47.9) 55.9 (23.7) 0.237
MIP, cmH2O 47.2 (8.7) 35.3 (16.7) 0.0003
MEP, cmH2O 85.8 (12.9) 67.5 (38.0) 0.004
Arterial blood gas
pH 7.42 (0.06) 7.41 (0.03) 0.517
PaCO2 (RA), mmHg 51.3 (6.5) 50.4 (6.2) 0.625
PaO2 (RA), mmHg 65.7 (14.0) 63.9 (11.3) 0.598
NPO
Saturation mean (%) 87.8 (9.25) 85.9 (8.2) 0.435
CT90 (%) 20.2 (16.9) 53.9 (34.4) <0.0001
6-min walk test, m 238.3 (57.5) 299 (83.7) 0.007
Values are presented as the number (%) or mean (standard
deviation).
a Comparison between restrictive thoracic disease (taken
together); OHS, obesity-hypoventilation syndrome and neuro-
muscular diseases; FEV1, forced expiratory volume in one sec-
ond; FVC, forced vital capacity; RV, residual volume; TLC, total
lung capacity; MIP, maximum inspiratory pressure; MEP,
maximum expiratory pressure; PaCO2(RA), arterial carbon diox-
ide tension (room air); PaO2 (RA), arterial oxygen tension (room
air); NPO, Nocturnal pulse oximetry; CT90 (%), percentage of
time with oxygen saturation below 90%.
Table 2 Baseline patient characteristics according to the
adaptation setting.
Ambulatory
adaptation
(n Z 27)
Hospital
adaptation
(n Z 26)
Age, years 64.6  13.1 65.5  13.2
Sex
Males 8 (29.6%) 11 (42.3%)
Smoker
Current 1 (3.7%) 2 (7.7%)
Past 8 (29.6%) 8 (30.8%)
Never 18 (66.7%) 16 (61.5%)
Disease
Restrictive thoracic disease 15 (55.6%) 14 (53.8%)
Kyphoscoliosis 8 (53.4%) 8 (57.2%)
Tuberculosis sequelae 5 (33.3%) 6 (42.8%)
Pleural thickening 2 (13.3%) 0 (0%)
OHS 5 (18.5%) 4 (15.4%)
Neuromuscular 7 (25.9%) 8 (30.8%)
Pulmonary function test
FVC, % predicted 41.9 (15.3) 46.5 (16.2)
FEV1, % predicted 43.5 (16.0) 44.0 (17.3)
FEV1/FVC, % 61.3 (25.0) 63.0 (19.8)
TLC, % predicted 62.7 (18.7) 70.5 (23.3)
RV, % predicted 77.0 (28.5) 94.2 (40.7)
RV/TLC, % 56.4 (24.4) 55.4 (23.4)
MIP, cmH2O 33.7 (18.7) 36.8 (14.8)
MEP, cmH2O 73.2 (49.5) 61.7 (21.0)
Arterial blood gas
pH 7.4 (0.0) 7.4 (0.0)
PaCO2 (RA) mmHg 50.4 (6.8) 50.3 (5.7)
PaO2 (RA) mmHg 64.4 (12.6) 63.4 (10.1)
NPO
Saturation mean (%) 87.5 (7.3) 84.1 (8.9)
CT90 (%) 47.9 (35.7) 60.40 (32.3)
6-min walk test, m 288.5 (78.6) 309.50 (89.3)
Values are presented as number (%) or mean (standard devia-
tion).
OHS, obesity-hypoventilation syndrome; FEV1, forced expira-
tory volume in one second; FVC, forced vital capacity; RV, re-
sidual volume; TLC, total lung capacity; MIP, maximum
inspiratory pressure; MEP, maximum expiratory pressure;
PaCO2(RA), arterial carbon dioxide tension (room air); PaO2 (RA),
arterial oxygen tension (room air); NPO, nocturnal pulse oxim-
etry; CT90 (%), percentage of time with oxygen saturation
below 90%.
1018 M. Pallero et al.At 6 months after starting ventilation, no differences in
objective compliance were found between the groups.
Mean compliance was 6.90 (2.56) hours per day in AA pa-
tients and 7.21 (2.52) hours per day in patients receiving HA
(pZ 0.3796). During follow-up, 40 unscheduled visits were
required in 35 patients (17 AA, 18 HA). Three patients
experienced exacerbation of their respiratory condition.
One (AA) was attended in the emergency room, whereas
the other two (HA) needed hospital admission, one in a
conventional ward and the other in the intensive care unit.
Adverse effects were similar in the two groups. Oral leaksoccurred in 11 patients (8 AA, 3 HA), nasal bridge erosion in
7 (5 AA, 2 HA), abdominal distension in 4 (2 AA, 2 HA),
claustrophobia in 3 (2 AA, 1 HA), and rhinitis in 1(HA). All
side effects were treated, and in order to overcome oral
leaks, a chin strap was prescribed.
Since the two adaptation strategies yielded a thera-
peutically equivalent outcome and non-inferiority was
established, we proceeded to apply the cost-minimization
approach to estimate the mean direct cost per patient of
each approach. The calculations resulted in a cost of 1500
euros in patients undergoing AA and 2692 euros in those
receiving HA (Table 6). The difference was mainly related
to the cost of the initiation phase (AA 541 euros, and HA
Table 3 Characteristics of noninvasive home mechanical ventilation according to adaptation setting.
Total (n Z 53) Ambulatory (n Z 27) Hospital (n Z 26) p
Nasal mask
Custom-made 9 (17.0%) 2 (7.4%) 7 (26.9%) 0.059
Commercial 44 (83.0%) 25 (92.6%) 19 (73.1%)
Type of ventilator
Volume 50 25 25 0.880
Pressure 3 2 1 NA
Tidal volume, mLa 793.2  248.9 773.7  179.0 808.0  293.9 0.635
Respiratory rate, cycles/min 17.16  2.79 16.63  2.59 17.56  2.92 0.279
Inspiratory/expiratory ratio
1/1 19 (41.3%) 9 (45%) 10 (38.4%) 0.601
1/1.2 12 (26.1%) 5 (25%) 7 (26.9%)
1/1.5 11 (23.9%) 5 (25%) 6 (23.2%)
1/2 4 (8.7%) 1 (5%) 3 (11.5%)
Inspiratory pressureb, cmH2O 18.00 (0.00) 18.00 (0.00) 18.00 (0.00) NA
Expiratory pressureb, cmH2O 6.67 (1.16) 7.00 (1.41) 6.00 (0.00) NA
O2 during ventilation 3 1 2 NA
ABG efficacyc
PH 7.47 (0.05) 7.47 (0.05) 7.47 (0.06) 0.587
PaCO2, mmHg 43.0 (8.4) 41.7 (7.8) 44.6 (9.0) 0.243
PaO2, mmHg 75.9 (11.8) 76.3 (10.2) 75.6 (13.7) 0.846
NPOd
Saturation (%) 92.2 (3.05) 92.1 (3.03) 92.4 (3.13) 0.688
CT90 (%) 19.1 (23.8) 20.8 (24.6) 17.4 (23.3) 0.615
Descriptive values indicate either n or n (%) or mean (standard deviation).
NA, not applicable; ABG, arterial blood gas; NPO, nocturnal pulse oximetry; CT90 (%), percentage of time with oxygen saturation below
90%; PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension.
a Parameter can only be set in volume ventilators (n Z 50).
b Parameter can only be set in pressure ventilators (n Z 3).
c Blood gas measurement performed in ventilator-adapted patient at 30 min after initiating first session.
d Nocturnal pulse oximetry performed with patients connected to noninvasive ventilation.
Ambulatory adaptation to noninvasive ventilation 10191886 euros); the follow-up period showed a much smaller
difference (AA 960 euros, and HA 806 euros).
Discussion
The results of this study show that starting NIMV in stable
patients with chronic respiratory failure secondary toTable 4 Respiratory test results at 6 months of follow-up and a
Ambulatory adaptation (n Z 27) Hosp
Descriptive
values
Absolute changes
from baseline
Desc
value
Mean (SD) p Mean [95% CI] Mean
FVC, % predicted 45.7 (16.01) 0.127 2.9 [6.7; 0.9] 46.5
FEV1, % predicted 47.5 (16.7) 0.225 2.7 [7.2; 1.8] 45.1
FEV1/FVC 62.1 (24.2) 0.992 0.0 [2.8; 2.8] 65.1
MIP, cmH2O 33.7 (25.6) 0.922 0.6 [13.3; 14.6] 43.3
MEP, cmH2O 70.8 (52.4) 0.659 4.3 [16.6; 25.3] 74.0
PaO2 (RA) mmHg 69.3 (9.7) 0.004 5.6 [9.3; 2.0] 69.0
PaCO2 (RA) mmHg 45.2 (4.6) 0.0008 4.9 [2.3; 7.4] 46.2
6MWT, m 305.5 (86.9) 0.219 16.5 [11.0; 43.9] 322.3
Descriptive values indicate n or n (%) or mean (standard deviation).
expiratory volume in one second; MIP, maximum inspiratory pressure
tension (room air); PaCO2 (RA),: arterial carbon dioxide tension (roomrestrictive thoracic disease, obesity-hypoventilation syn-
drome or neuromuscular disease in the outpatient setting is
not inferior in terms of therapeutic effectiveness and less
costly than inhospital adaptation. To our knowledge, this is
the first clinical trial evaluating therapeutic effectiveness
and cost related to outpatient versus inhospital NIMV
adaptation. The large sample size of this study and thebsolute changes from baseline.
ital adaptation (n Z 26) Differences between
groupsriptive
s
Absolute changes
from baseline
(SD) p Mean [95% CI] p Mean [95% CI]
(15.6) 0.822 0.3 [2.9; 2.3] 0.229 2.6 [1.7; 7.0]
(16.2) 0.543 0.8 [3.2; 1.8] 0.422 1.9 [2.9; 6.8]
(19.0) 0.924 0.2 [3.4;3.2] 0.938 0.2 [4.4; 4.41]
(21.8) 0.207 6.8 [4.2; 17.8] 0.454 6.2 [22.8; 10.5]
(31.0) 0.147 12.9 [5.1; 30.8] 0.509 8.5 [34.70; 17.6]
(9.5) 0.017 4.9 [0.9; 8.9] 0.781 0.7 [4.5; 6.0]
(5.2) 0.001 3.3 [1.4; 5.1] 0.304 1.6 [4.6; 1.5]
(74.1) 0.504 9.7 [20.2; 39.5] 0.732 6.8 [33.2; 46.8]
SD, standard deviation; FVC, forced vital capacity; FEV1, forced
; MEP, maximum expiratory pressure; PaO2 (RA), arterial oxygen
air); 6MWT: 6-min walk test.
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1020 M. Pallero et al.prospective randomized design, support that our results
can be considered highly reliable.
Outpatient versus inpatient adaptation to NIMV has been
addressed in 2 previous studies: a randomized trial without
pharmacoeconomic assessment [11] and an observational
study including cost analysis [12]. Chatwin et al. [11] per-
formed a study randomizing the type of adaptation,
although only 28 patients were included (14 per adaptation
group) and a cost analysis was not performed. Although the
results obtained were similar to those of the present study
and both have demonstrated an improvement in quality of
life in patients undergoing ambulatory adaptation, the two
studies have substantial differences. Chatwin et al.
included patients at least 12 years of age, none had
obesity-hypoventilation syndrome, and NIMV was estab-
lished at a less advanced phase of the disease. This may be
related to the selection criteria used. Whereas Chatwin
et al. included patients showing nocturnal transcutaneous
carbon dioxide tension greater than 6.5 KPa (48.75 mmHg)
for more than 50% of the night, in the present study, the
selection criterion was mainly a diurnal PaCO2 level greater
than 45 mmHg.
Our study is the first to apply a prospective, methodo-
logically objective approach to the decision of indicating
one or another adaptation strategy for NIMV, based on
clinical and arterial blood gases parameters of effective-
ness and considering the cost for the healthcare system.
Lujan et al. [12] also performed a cost analysis, calculating
the savings gained by avoiding hospitalization of patients,
and reported that ambulatory adaptation results in a 53%
cost saving. In contrast to Lujan’s study, in which the cost
evaluation was focused solely on the initial adaptation to
ventilation, the present study encompasses direct costs in
the initial phase as well as those generated during follow-
up after NIMV has been implemented. Thus, we found
that AA is more efficient than HA, involving a 71% cost
reduction in the initial phase and a saving of 44% in the
overall adaptation phase, making it a cost-effective strat-
egy for the health system.
Although this study is a randomized clinical trial, it has
several potential limitations. One is the lengthy time in-
terval between randomization and the start of treatment,
which could explain the high number of randomized pa-
tients in whom it was not possible to start ventilation.
Although the waiting time was longer in patients under-
going hospital adaptation, the number of patients who
were not treated was similar in the two groups. Another
limitation is the use of volume ventilators. Volume-cycled
ventilation was the modality commonly used in Europe
when ventilation therapy was introduced, but now most
groups prefer pressure-cycled ventilation [10]. Some
studies have suggested that volume-cycled ventilation
may be more effective in patients with severe respiratory
failure and advanced phases of disease [25,26], but two
randomized controlled trials have found no differences
between these modalities [27,28]. Another potential lim-
itation of this study is the use of nocturnal pulse oximetry
and diurnal arterial blood gases measurement in the set
up and monitoring effectiveness of the ventilation.
Although it has been recently proposed to use the poly-
somnography or transcutaneous carbon dioxide for
adjusting ventilation [29], these measurements are not
Table 6 Comparison of direct cost between the two adaptation approaches.
Cost ambulatory
adaptation, V (n Z 27)
Cost hospital adaptation,
V (n Z 26)
Difference, V
Initiation Days hospitalized 49,023 49,023
Health resource use:
Physician 12,158 12,158
Nursing 2436 2436
Total 14,594 49,023 34,429
Total per patient 541 1886 1345
Follow-up (6 months) Hospitalization:
Emergency unit 253 253
Hospital wards 5237 5237
Intensive care unit 951 951
Unscheduled visits
Related to NIMV 4654 6056 1402
Unrelated to No NIMV 2430 2543 113
Scheduled visits 2326 2284 42
Additional tests:
Pulmonary function test 2238 2091 147
6-min walk test 964 1015 51
Arterial blood gas 7107 6718 389
Total 25,907 20,960 4947
Total per patient 960 806 154
Final direct cost 40,501 69,981 29,480
Cost per patient 1500 2692 1192
Values are expressed in euros (V).
NIMV, noninvasive mechanical ventilation.
Ambulatory adaptation to noninvasive ventilation 1021always available in centers establishing NIMV [10,30].
Furthermore, the PaCO2 with the patient breathing room
air at 1 month after starting NIMV has proved to be a
predictor for mortality in patients ventilated with chest
wall disease [31,32]. Lastly, the cost analysis was per-
formed with direct expenditure and only contemplated
the cost of labor and resources for adaptation. Indirect
costs, such as transportation to the hospital for patients,
and work time missed by both patients and their care-
givers were not considered. It should be mentioned that
the cost difference depended in great part on the duration
of hospitalization. The number of hours that ventilation
was used during the adaptation period was similar in the
two groups, even though HA patients were directly su-
pervised by the health staff. HA and AA adaptation did not
seem to have an influence on better compliance with
treatment at long term either.
In conclusion, initiation of NIMV in the ambulatory
setting for stable and selected patients with restrictive
thoracic disease, obesity-hypoventilation syndrome or
slowly progressive neuromuscular diseases, is not thera-
peutically inferior to hospital-based adaptation. In addi-
tion, it is a more accessible strategy that reduces the
waiting time to establish NIMV treatment, it represents a
cost saving for the healthcare system, and it spares the
use of resources for the population requiring hospitaliza-
tion. Therefore, in the light of these findings, it would be
advisable to carry out new studies in other healthcare
systems to better determine which patients can
benefit from this approach to be used in routine clinical
practice.Conflict of interest statement
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